Opening the book…
Selected Title 21 Regulations for Biotechnology
Title 21 of the Code of Federal Regulations (CFR) covers many activities in biotechnology, from keeping electronic records to labeling drugs and reporting problems with medical devices. The examples below can help you find the right part of Title 21. Start by reading the regulation’s scope. It tells you which products, records, or activities the requirements cover.
21 CFR Part 11 — Electronic Records and Electronic Signatures
Part 11 sets criteria for making covered electronic records and signatures trustworthy and reliable. To determine whether it applies, start with the underlying FDA requirement and look at how the organization uses the record. For example, an electronic batch record a company relies on to meet an FDA recordkeeping requirement may fall under Part 11. Simply saving a file on a lab computer does not bring it within the rule’s scope. FDA guidance on the scope and application of Part 11
21 CFR Part 201 — Labeling
Drug labeling helps people identify a product, understand what it is for, and learn how to use it. The sections below show how Part 201 addresses specific labeling questions. The full set of requirements depends on the product.
| Section | What it covers |
|---|---|
| § 201.1 | How the label identifies the manufacturer, packer, or distributor and gives its place of business. |
| § 201.5 | What counts as adequate directions for use. Exemptions may apply under other sections. |
| § 201.15 | How required information must be displayed so people can notice and read it. |
| § 201.17 | Where the expiration date must appear when one is required. |
| § 201.117 | A narrow exemption from adequate directions for use for certain substances intended for use as inactive ingredients. |
| § 201.122 | The conditions for an exemption from adequate directions for use when a drug is intended for processing, repacking, or use in manufacturing another drug. |
| § 201.128 | How the FDA determines a product’s intended use. Evidence can include labeling, advertising, and the circumstances of distribution. |
21 CFR Part 314 — Applications for FDA Approval to Market a New Drug
Part 314 covers how companies apply for FDA approval to market a drug. It includes new drug applications and abbreviated new drug applications, which are used for generics. It also covers responsibilities after approval, such as reporting certain changes to how a drug is made. 21 CFR Part 314
21 CFR Part 610 — General Biological Products Standards
Part 610 sets standards for biological products. It covers areas such as product testing, labeling, and other quality controls. Which requirements apply depends on the specific biological product. 21 CFR Part 610
21 CFR Part 803 — Medical Device Reporting
Part 803 explains when certain deaths, serious injuries, and malfunctions involving medical devices must be reported. The duties differ for manufacturers, importers, and device user facilities. These reports help the FDA spot possible safety problems after devices are in use. 21 CFR Part 803
21 CFR Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products
Part 1271 covers certain products made from or consisting of human cells or tissues. It addresses topics such as registering facilities, determining whether donors are eligible, and following practices that reduce the risk of spreading communicable disease. Depending on the product and its intended use, drug, biologic, or medical device requirements may also apply. 21 CFR Part 1271
This page titled 11.6: Selected Regulations Relevant to Biotechnology was last modified on Tue, 03 Nov 2026 08:06:36 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.